ARS Pharmaceuticals has appointed Donn Casale as its new Chief Executive Officer, effective July 7. Casale, who previously served as the company's President, succeeds co-founder Richard Lowenthal, whose employment ended on July 6. Casale brings over 25 years of biopharma and commercial leadership experience, including a role as Chief Commercial Officer at Dynavax Technologies where he helped scale annual revenues of the hepatitis B vaccine HEPLISAV-B to more than $300 million and achieve over 50% U.S. market share before Sanofi acquired Dynavax for $2.2 billion. The leadership change comes as ARS Pharmaceuticals continues to work on payer access for neffy, its needle-free epinephrine nasal spray for anaphylaxis, with no new coverage decisions reported in the July 1 cycle.
ARS Pharmaceuticals, IncCEO change is a leadership event; impact on company performance is uncertain.
Sanofi SA